Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampin on the Pharmacokinetics of Oral HRS-8080 in Healthy Participants
NCT07876596Phase 1Not yet recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Nov 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-8080 in breast cancer, sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Peak concentration, Area under the serum concentration-time curve from time zero to the last quantifiable concentration and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
HRS-8080
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07876596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07876596.